bpc-157 pharmacokinetics half-life study and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase bpc-157 oral bioavailability pharmacokinetics study

It remains an investigational peptide used in clinical and research settings outside of formal FDA-approved indications

doi:10.1038/srep22386

NICE Clinical Knowledge Summaries recommend B12 injections for: Pernicious anaemia an autoimmune condition affecting intrinsic factor production Malabsorption syndromes including coeliac disease and inflammatory bowel disease Post-surgical states particularly following gastrectomy or ileal resection Strict vegan diets when oral supplementation proves inadequate, though oral cyanocobalamin is usually sufficient for dietary deficiency Clinical trials demonstrate that B12 injections rapidly improve haematological parameters and neurological symptoms when deficiency is confirmed through blood tests

Same syringe